Review the Successes of 2017 and Look to the Future of AMR
Christopher Houchens of BARDA talks about Incentivizing Antibacterial Research and Development SMi’s Superbugs & Superdrugs Conference 2018
London, United Kingdom, January 03, 2018 --(PR.com)-- London, 19 - 20 March 2018 SMi’s Superbugs & Superdrugs Conference 2018 will gather a high level of international experts and project decision makers to review the successes of 2017 and look to the future of AMR. Two full days of information, education and networking not to be missed.
Christopher Houchens, Branch Chief, Biomedical Advanced Research and Development Authority joining the top speaker panel. His presentation on Incentivizing Antibacterial Research and Development will answer your questions on why is BARDA interested in AMR; how BARDA partners with industry to stimulate innovation in AMR R&D; how CARB-X is refilling the preclinical AMR product pipeline.
All participants will gain the knowledge and get informed on the latest development within scientific communities and on strategies pharmaceutical companies using to develop novel therapeutics.
There will also be a large focus on novel candidates and alternatives to antimicrobials; Greater coverage of the regulations, further funding possibilities and partnerships and strategies.
The workshop on March, 21st will focus on the transition from in vitro activity to in vivo efficacy, the choice of the right animal model for proof of concept studies, provide examples of relevant animal models with supportive data and interpretation of results as they relate to the clinical condition.
You will: gain an understanding of what animal models can and cannot provide; learn how animal model endpoints relate to clinical endpoints; access in depth discussion of how models are performed; get insights on regulations and constraints in the performance of these models.
Further details including a full speaker line-up and detailed programme are available at http://www.superbugssuperdrugs.com/prcomjan
Sponsored by MSD
Contact Information:
For all media enquiries contact Lyudmyla Durneva on Tel: T: +44 (0) 207 827 6088 | LDurneva@smi-online.co.uk
For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Christopher Houchens, Branch Chief, Biomedical Advanced Research and Development Authority joining the top speaker panel. His presentation on Incentivizing Antibacterial Research and Development will answer your questions on why is BARDA interested in AMR; how BARDA partners with industry to stimulate innovation in AMR R&D; how CARB-X is refilling the preclinical AMR product pipeline.
All participants will gain the knowledge and get informed on the latest development within scientific communities and on strategies pharmaceutical companies using to develop novel therapeutics.
There will also be a large focus on novel candidates and alternatives to antimicrobials; Greater coverage of the regulations, further funding possibilities and partnerships and strategies.
The workshop on March, 21st will focus on the transition from in vitro activity to in vivo efficacy, the choice of the right animal model for proof of concept studies, provide examples of relevant animal models with supportive data and interpretation of results as they relate to the clinical condition.
You will: gain an understanding of what animal models can and cannot provide; learn how animal model endpoints relate to clinical endpoints; access in depth discussion of how models are performed; get insights on regulations and constraints in the performance of these models.
Further details including a full speaker line-up and detailed programme are available at http://www.superbugssuperdrugs.com/prcomjan
Sponsored by MSD
Contact Information:
For all media enquiries contact Lyudmyla Durneva on Tel: T: +44 (0) 207 827 6088 | LDurneva@smi-online.co.uk
For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Lyudmyla Durneva
+44 (0) 20 7827 6138
http://www.superbugssuperdrugs.com/prcomjan
Lyudmyla Durneva
+44 (0) 20 7827 6138
http://www.superbugssuperdrugs.com/prcomjan
Contact
Categories